-       Report 
   - August 2025
    -  184 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  190 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  183 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  194 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                   -       Report 
   - August 2025
    -  186 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  199 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  197 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  194 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  198 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  199 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  183 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  199 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - November 2024
    -  172 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - November 2025
    -  402 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - September 2025
    -  200 Pages 
    Global
   
   From       €2683EUR$2,990USD£2,355GBP 
                -       Report 
   - January 2025
    -  200 Pages 
    Global
   
   From       €2234EUR$2,490USD£1,961GBP 
                -       Report 
   - March 2025
    -  182 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - November 2025
    -  194 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  183 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
             
          The Urological Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat urological disorders. These disorders include urinary tract infections, bladder control issues, kidney stones, prostate cancer, and erectile dysfunction. Companies in this market develop and market drugs that can help to reduce the symptoms of these disorders, as well as provide treatments for them.
Some of the major players in the Urological Disorders    Drugs market include Pfizer, Merck, AstraZeneca, GlaxoSmithKline, and Sanofi. These companies have a wide range of products that are used to treat urological disorders, including antibiotics, antifungals, and anti-inflammatory drugs. Additionally, they have developed drugs that can help to reduce the symptoms of these disorders, such as pain relievers and muscle relaxants. Show Less   Read more